| Autor: |
Lance Heilbrun, Anthony Shields, Jawana Lawhorn-Crews, Karen Baranowski, Daryn Smith, Lawrence Flaherty |
| Předmět: |
|
| Zdroj: |
Investigational New Drugs; Feb2007, Vol. 25 Issue 1, p69-75, 7p |
| Abstrakt: |
Summary Objectives: To evaluate the toxicity and efficacy of interferon and thalidomide combination in a phase II clinical trial.Patients and methods: Eligibility included metastatic renal cancer with a maximum of two prior regimens, performance status of 0â2 and adequate renal, hepatic and bone marrow function.Results: Twenty patients were enrolled on this phase II trial. Median age was 60.5 years (Range: 39â75 years). 17 patients had visceral metastases (lung/liver/both) and 3 patients had lymph node only metastases. A total of 26 cycles of 4 weeks each were administered; median of 1 cycle and range from 0â9 cycles. The therapy was poorly tolerated with grade 3 adverse events noted in 12 (60%) of the 20 patients. No objective responses were noted. Of the 14 response evaluable patients, one had an unconfirmed response (38% decrease in size) and one had prolonged disease stabilization for 10 months. The median time to progression was 1.0 month and median survival was 2.8 months. Pre and post therapy PET scans were performed nine weeks apart on one patient. The mean standardized uptake values (SUV) declined from 1.45 (SUV min-max 0.89â1.76) to 1.12 (SUV min-max 0.55â1.47), denoting anti vascular effect. The patient did not have an objective response but had a disease stabilization sustained for 10 months.Conclusion: The combination of interferon and thalidomide has minimal efficacy and considerable toxicity which makes this combination unworthy of future investigation in metastatic renal cancer. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink